Analysis BioNTech’s Board Expansion Signals Oncology Pivot — But the Market Still Wants Proof
The story of BioNTech has shifted from pandemic winner to pipeline builder, and the transition is proving uncomfortable. Investors have watched the stock slide nearly 22% over the past year,...